Compass Pathways’ (CMPS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Compass Pathways (NASDAQ:CMPS) in a research note released on Monday morning,Benzinga reports. HC Wainwright also issued estimates for Compass Pathways’ Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.40) EPS, Q1 2027 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.31) EPS, Q3 2027 earnings at ($0.29) EPS, Q4 2027 earnings at ($0.25) EPS and FY2027 earnings at ($1.17) EPS.

A number of other research analysts have also recently commented on the stock. B. Riley Financial increased their price target on shares of Compass Pathways from $17.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Royal Bank Of Canada restated an “outperform” rating on shares of Compass Pathways in a report on Wednesday, November 4th. Oppenheimer restated an “outperform” rating and issued a $20.00 price objective on shares of Compass Pathways in a report on Tuesday, November 3rd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Compass Pathways in a research note on Wednesday, September 9th. Finally, Morgan Stanley increased their target price on shares of Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $23.14.

Compass Pathways Price Performance

CMPS opened at $9.30 on Monday. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $1.32 billion, a P/E ratio of -2.66 and a beta of 2.43. The stock has a 50-day moving average price of $12.06 and a 200-day moving average price of $10.44. Compass Pathways has a 12-month low of $4.88 and a 12-month high of $15.87.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.08. Equities analysts predict that Compass Pathways will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Pathways

A number of hedge funds and other institutional investors have recently modified their holdings of CMPS. Eagle Health Investments LP boosted its holdings in Compass Pathways by 35.6% during the 1st quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company’s stock valued at $11,394,000 after acquiring an additional 541,039 shares during the period. Candriam S.C.A. increased its stake in Compass Pathways by 18.6% in the 3rd quarter. Candriam S.C.A. now owns 1,510,695 shares of the company’s stock worth $18,862,000 after purchasing an additional 236,417 shares during the period. Creek Drive Management Group LLC increased its stake in Compass Pathways by 91.9% in the 3rd quarter. Creek Drive Management Group LLC now owns 1,328,000 shares of the company’s stock worth $16,520,000 after purchasing an additional 636,000 shares during the period. Orbimed Advisors LLC purchased a new position in Compass Pathways in the 1st quarter worth approximately $6,363,000. Finally, Affinity Asset Advisors LLC lifted its position in Compass Pathways by 454.2% in the first quarter. Affinity Asset Advisors LLC now owns 1,108,483 shares of the company’s stock valued at $6,130,000 after purchasing an additional 908,483 shares during the last quarter. Institutional investors own 46.19% of the company’s stock.

Key Compass Pathways News

Investors following CMPS have been watching these news items:

• Positive Sentiment: HC Wainwright’s updated estimates project narrower losses: its FY2026 EPS forecast improved to ($1.40) from ($1.58), and its FY2027 forecast to ($1.17) from ($1.56). The firm also raised estimates across the reported quarters through 2027 and maintained its Buy rating. Better-than-previous forecasts may support investor sentiment, though the company is still expected to post losses. Compass Pathways analyst estimates
• Neutral Sentiment: Compass Pathways plans to attend the Jefferies Global Healthcare Conference on November 18–19, including a fireside chat and panel. The appearance could provide investor visibility, but the announcement did not disclose new company developments. Conference announcement

About Compass Pathways

Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.